Publications by authors named "Hartmut M Lode"

Claim this Profile
T
The clinical positioning of telavancin in Europe.
Robert Masterton, Giuseppe Cornaglia, Patrice Courvalin, Hartmut M Lode, Jordi Rello

Int J Antimicrob Agents· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preserving the efficacy of front-line fluoroquinolones through selective use to optimise clinical outcomes.
Hartmut M Lode

Int J Antimicrob Agents· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risks associated with the therapeutic use of fluoroquinolones.
Ralf Stahlmann, Hartmut M Lode

Expert Opin Drug Saf· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Moxifloxacin: update and perspectives after 8 years of usage.
Hartmut M Lode, Malina Schmidt-Ioanas

Expert Rev Respir Med· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rational antibiotic therapy and the position of ampicillin/sulbactam.
Hartmut M Lode

Int J Antimicrob Agents· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemifloxacin for community-acquired pneumonia.
Hartmut M Lode, Malina Schmidt-Ionas, Ralf Stahlmann

Expert Opin Investig Drugs· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Managing community-acquired pneumonia: a European perspective.
Hartmut M Lode

Respir Med· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Uses in in ambulatory and stationary situations. Clinical indications for beta lactams].
Hartmut M Lode

Pharm Unserer Zeit· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis